Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* CD4 count of 300 cells/mm3 or more~* Access to a HAART regimen consisting of 1 or more protease inhibitors (PIs) and 2 or more nucleoside or nucleotide reverse transcriptase inhibitors~Exclusion Criteria:~* Prior use of aldesleukin~* Approved or experimental antiretroviral drug (including hydroxyurea) within 1 year prior to study entry~* Evidence of virologic failure on a PI- or nonnucleoside-based HAART regimen~* Any current indication for continuous HAART, in the opinion of the investigator~* Any contraindication to HAART, in the opinion of the investigator~* Systemic corticosteroids, chemotherapy, or experimental cytotoxic drugs within 45 days of randomization~* Approved or experimental agents with clinically significant immunomodulatory effects within 8 weeks prior to randomization~* History of any AIDS-defining illness or certain other diseases. More information on this criterion can be found in the protocol.~* Concurrent cancer requiring cytotoxic therapy~* Any central nervous system (CNS) abnormality requiring ongoing treatment with antiseizure medication~* Current or prior autoimmune or inflammatory diseases, including inflammatory bowel disease, psoriasis, optic neuritis, or any other autoimmune or inflammatory diseases with potentially life-threatening complications~* Significant heart, lung, kidney, liver, gastrointestinal, CNS, or psychiatric disease OR illicit substance use or abuse that, in the opinion of the investigator, would interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No IL-2 (Type: NO_INTERVENTION): Participants will receive no aldesleukin or HAART
- IL-2 without ART (Type: EXPERIMENTAL): Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
- IL-2 with pericycle HAART (Type: EXPERIMENTAL): Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete